Displaying 921 - 940 of 1505
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
FTC Releases Report on Follow-on Biologic Drug Competition
Chairman, Commissioners Issue Statement on Endocare, Inc.s Announcement That it has Terminated its Merger Agreement with Galil Medical Ltd.
Statement of the FTC's Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics
FTC Settles Price-Fixing Charges Against San Francisco Bay Area Doctors Group
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
FTC Staff Advises Louisiana Legislature That Amended Bill Would Further Restrict Competition to Provide Dental Care to States Most Vulnerable Children
FTC Staff Advises Louisiana Legislature That Bill Would Restrict Competition to Provide Dental Care to the State's Underserved Children; At FTC's Request, District Court Halts Illegal Operations of Federal Loan Modification Law Center
FTC Staff Advises Maryland Physician-Hospital Organization That it Will Not Recommend Antitrust Challenge to Proposal to Provide Member Physicians Services Through Clinical Integration Program
FTC Staff Comment Says New York Bill to Regulate Pharmacy Benefit Managers May Increase Pharmaceutical Prices for New York Consumers; Commission Approves Final Consent Order in Matter of Dow Chemical Company and Rohm & Haas Company
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
Bristol-Myers Squibb to Pay $2.1 Million Penalty for Failure to Disclose Agreement Involving Substantial Payments to Delay Entry of a Generic Version of the Drug Plavix
FTC Staff Comment Says Bills to Authorize Collective Bargaining by Minnesota Health Care Cooperatives will Raise Health Care Costs for Minnesota Consumers
Getinge AB and Datascope Corp., In the Matter of
The Commission challenged Getinge AB’s proposed $865 million acquisition of rival Datascope Corporation as anticompetitive in the market for endoscopic vessel harvesting devices (EVHs). EVHs are used during coronary artery bypass graft surgery where a vein is removed from a patients leg or arm to replace a damaged or blocked coronary artery. According to the Commission’s complaint, the acquisition as proposed would give Getinge nearly a 90% market share and the ability to unilaterally increase prices while reducing the likelihood of innovation. The Commission issued a consent order requiring that Datascope divest its EVH assets to Sorin Group USA within 10 days of consummating the transaction.
Displaying 921 - 940 of 1505